盐皮质激素受体拮抗剂治疗糖尿病肾病研究进展  

Research progress on mineralocorticoid receptor antagonist in the treatment of diabetic nephropathy

作　　者：杨叶萍 张朝云 YANG Yeping;ZHANG Zhaoyun(Department of Endocrinology,Huashan Hospital,Fudan University,Shanghai 200040,China)

机构地区：[1]复旦大学附属华山医院内分泌科,上海200040

出　　处：《世界临床药物》2023年第9期895-898,共4页World Clinical Drug

基　　金：国家自然科学基金项目(82170841、81970716、82100882、82200921);中华国际医学交流基金项目(Z-2017-26-1902);上海医苑新星杰出人才培养计划(3030255001)。

摘　　要：糖尿病肾病(diabetic nephropathy,DN)是导致终末期肾病(end-stage renal disease)的主要因素,但目前治疗药物种类及效果均有限。盐皮质激素受体拮抗剂(mineralocorticoid receptor antagonist,MRA)对DN患者具有一定肾脏保护作用,其机制可能与抑制炎症、减少肾脏纤维化及改善氧化应激失衡等有关。现就MRA对DN的影响作进一步归纳、总结,旨在为临床诊治提供一定参考。Diabetic nephropathy(DN)is the main factor leading to end-stage renal disease,but the types and effects of current therapeutic drugs are limited.Mineralocorticoid receptor antagonist(MRA)has certain renal protection effect in patients with DN,and its mechanism may be related to inhibiting inflammation,reducing renal fibrosis and improving oxidative stress imbalance.This article further summarized the effects of MRA on DN,in order to provide some reference for clinical diagnosis and treatment.

关 键 词：盐皮质激素受体拮抗剂 糖尿病肾病 肾脏纤维化 

分 类 号：R587.1[医药卫生—内分泌] R692.9[医药卫生—内科学]